Christopher J. Patterson

Author

Also Known As

C J Patterson, C. J. Patterson, C. Patterson, C.J. Patterson, Caroline A. Patterson, Christopher B. Patterson, Christopher J Patterson, Christopher J. Patterson, Christopher J. S. Patterson, Christopher J.S. Patterson

298

Publications

10K

Citations

H-Index

112

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Boston University Massachusetts General Hospital Brigham and Women's Hospital

About

Christopher J. Patterson is an author at Dana-Farber Cancer Institute specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	31	1.6K
2	Health Sciences	7	7	299
3	Nursing	2	2	31
4	Public Health	2	2	37
5	Allergy	1	1	29

Christopher J. Patterson

101

Publications

8.8K

Citations

H-Index

Page 1

	Year	Citations
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia Steven P. Treon, Lian Xu, Guang Yang, New England Journal of Medicine	2012	1.3K
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia Steven P. Treon, Christina Tripsas, Kirsten Meid, New England Journal of Medicine	2015	913
The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis Zachary R. Hunter, Lian Xu, Guang Yang, Blood	2013	470
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction Lian Xu, Zachary R. Hunter, Guang Yang, Blood	2013	407
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia Guang Yang, Yangsheng Zhou, Xia Liu, Blood	2013	343
Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180 Steven P. Treon, Leukothea Ioakimidis, Jacob D. Soumerai, Journal of Clinical Oncology	2009	287
Response assessment in <scp>W</scp>aldenström macroglobulinaemia: update from the <scp>VI</scp>th <scp>I</scp>nternational <scp>W</scp>orkshop Roger G. Owen, Robert A. Kyle, Marvin J. Stone, British Journal of Haematology	2012	264
The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia Yang Cao, Zachary R. Hunter, Xingguang Liu, Leukemia Somatic VariantNovel TherapyMedicineImmunologyOther Agents	2014	231
Characterization of familial Waldenström's macroglobulinemia Steven P. Treon, Zachary R. Hunter, Abha Aggarwal, Annals of Oncology Genetic DisorderHematologyHistopathologyGenetic EpidemiologyPathology	2005	189
Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside Analogs Xavier Leleu, Jacob D. Soumerai, Aldo M. Roccaro, Journal of Clinical Oncology	2008	182

Page 1